Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THETIS: Deferasirox in Non-Transfusion Dependent Thalassemia with Iron Overload
2012-000650-64Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in Thalassaemia and iron overload, sponsored by Novartis. Primary endpoint: Change in liver iron concentration (LIC) from baseline. Started Sep 2012; status: completed.
02
Drugs
deferasirox
03
Conditions
Thalassaemiairon overload
Beyond the preview
Go deeper on 2012-000650-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000650-64.